title: Advances with vaccination against Neisseria meningitidis.
abstract: In the last decade, meningococcal serogroup C conjugate vaccination programs have been demonstrated to be hugely successful with a truly impressive public health impact. In sub-Saharan Africa, with the implementation of an affordable serogroup A conjugate vaccine, it is hoped that a similar public health impact will be demonstrated. Challenges still remain in the quest to develop and implement broadly protective vaccines against serogroup B disease. New, broad coverage vaccines against serogroup B are for the first time becoming available although little is known about their antibody persistence, effectiveness or effect on nasopharyngeal carriage. Enhanced surveillance following any potential vaccine introduction against serogroup B needs to be thoroughly implemented. The future now holds a distinct possibility, globally, for substantially decreasing meningococcal disease, regardless of infecting serogroup.
authors.affiliation: Vaccine Evaluation Unit, Health Protection Agency, Manchester Royal Infirmary, Manchester, UK.
authors.forename: Ray
authors.initials: R
authors.lastname: Borrow
mesh_terms: D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology; D006801:Humans; D008589:Meningococcal Infections / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000276:immunology; D038541:Neisseria meningitidis, Serogroup B / Q000235:genetics / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology; D018074:Vaccines, Conjugate
chemical_list: D001426:Bacterial Proteins; D022401:Meningococcal Vaccines; D011994:Recombinant Proteins; D018074:Vaccines, Conjugate